Chad Dubbelde appointed as ๐๐ถ๐ฟ๐ฒ๐ฐ๐๐ผ๐ฟ, ๐๐๐ข ๐ฆ๐ฎ๐น๐ฒ๐ at Samsung Biologics โ ๐๐ฑ๐๐ฎ๐ป๐ฐ๐ถ๐ป๐ด ๐๐น๐ผ๐ฏ๐ฎ๐น ๐๐ถ๐ผ๐ฝ๐ต๐ฎ๐ฟ๐บ๐ฎ ๐ง๐ต๐ฟ๐ผ๐๐ด๐ต ๐ง๐ฟ๐ฎ๐ป๐๐ณ๐ผ๐ฟ๐บ๐ฎ๐๐ถ๐๐ฒ ๐ฃ๐ฎ๐ฟ๐๐ป๐ฒ๐ฟ๐๐ต๐ถ๐ฝ๐
Samsung Biologics proudly announces the appointment of Chad Dubbelde as Director, CDO Sales, effective June 2025. With a distinguished career that bridges cutting-edge science, strategic business development, and client-focused growth, Chad brings over two decades of experience to one of the worldโs leading biopharmaceutical contract development and manufacturing organizations (CDMOs).
This milestone appointment reflects Samsung Biologicsโ commitment to accelerating biopharma innovation, driving transformative partnerships, and delivering next-generation biologics to patients worldwide.
๐ฃ๐๐๐ต๐ถ๐ป๐ด ๐๐ต๐ฒ ๐๐ผ๐๐ป๐ฑ๐ฎ๐ฟ๐ถ๐ฒ๐ ๐ผ๐ณ ๐๐๐ ๐ข ๐๐ ๐ฐ๐ฒ๐น๐น๐ฒ๐ป๐ฐ๐ฒ
Samsung Biologics leverages its unrivaled expertise in biologics development to deliver tailored CDMO solutions that support clients from gene to IND and beyond. In his role as Director of CDO Sales, Chad is tasked with fostering trust-driven collaborations, accelerating clinical milestones, and advancing large molecule therapeutics into the clinic with speed, precision, and reliability.
Speaking about his vision, Chad noted:
โEvery partnership we build has the potential to transform patient outcomes. At Samsung Biologics, I see an incredible opportunity to not only support clients in their journey from discovery to development, but also to redefine whatโs possible in biologics innovation.โ
๐๐ฒ๐ฎ๐ฑ๐ฒ๐ฟ๐๐ต๐ถ๐ฝ ๐ฅ๐ผ๐ผ๐๐ฒ๐ฑ ๐ถ๐ป ๐๐ ๐ฝ๐ฒ๐ฟ๐ถ๐ฒ๐ป๐ฐ๐ฒ
Chadโs professional journey demonstrates a consistent ability to connect scientific insight with strategic business execution. At Charles River Laboratories, where he spent over six years, Chad played a pivotal role in shaping the biologics testing solutions business.
- As Business Development Director (2024โ2025), he drove client acquisition in the Boston market, building solutions that emphasized collaboration and client-centricity.
- As Regional Sales Manager for Western North America (2022โ2023), he expanded market reach in San Diego, establishing regional leadership in biologics testing.
- Earlier as Business Development Director (2019โ2021), he laid the foundation for long-term growth by combining technical acumen with strategic account management.
Through these roles, Chad solidified his reputation for a results-driven, customer-focused approach that seamlessly integrates scientific expertise with business strategy.
๐ ๐๐ถ๐๐ฒ๐ฟ๐๐ฒ ๐๐ผ๐๐ฟ๐ป๐ฒ๐ ๐ผ๐ณ ๐๐บ๐ฝ๐ฎ๐ฐ๐
Beyond Charles River, Chadโs career reflects a wide-ranging impact across industries:
- At BioSurplus (2016โ2019), he supported life sciences innovation by providing laboratory solutions tailored to research needs.
- At Cargill (2008โ2013), he drove 10% CAGR revenue growth in the specialty chemical sector through transformative marketing and product strategies.
- As an Independent Consultant (2007โ2008), he advised C-level executives with deep market research, financial valuation models, and strategic feasibility studies.
Earlier in his career, Chad laid a strong scientific foundation with research positions at Adaptive Therapeutics, Elitra Pharmaceuticals, Howard Hughes Medical Institute (HHMI), and Washington University School of Medicineโs Genome Institute, contributing to infectious disease therapeutics and the Human Genome Project.
๐๐ต๐ฎ๐ฟ๐๐ถ๐ป๐ด ๐ฎ ๐ก๐ฒ๐ ๐๐ผ๐๐ฟ๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐ถ๐ผ๐ฝ๐ต๐ฎ๐ฟ๐บ๐ฎ
In joining Samsung Biologics, Chad steps into a role that is not just about sales, but about shaping the future of biopharmaceutical partnerships. His mission is to connect science with strategy, innovation with execution, and ambition with outcomes.
โScience alone doesnโt change the worldโscience delivered with purpose does,โ Chad reflects. โAt Samsung Biologics, I am committed to helping clients navigate complexity, accelerate innovation, and bring life-saving therapies to patients faster than ever before.โ
๐ง๐ต๐ฒ ๐ฅ๐ผ๐ฎ๐ฑ ๐๐ต๐ฒ๐ฎ๐ฑ
Chadโs appointment signals a new chapter of growth and innovation for Samsung Biologics. With his unique blend of research expertise, commercial leadership, and visionary thinking, he is poised to play a transformative role in advancing the companyโs mission and shaping the future of the global biopharma ecosystem.
Samsung Biologics continues to stand at the forefront of biologics innovation โ and with leaders like Chad driving its mission forward, the company is well-positioned to redefine what partnership, progress, and patient impact truly mean in the biopharmaceutical industry.
This announcement is proudly featured on CXO Gateway, a platform that highlights visionary leadership and celebrates executives driving transformation across industries. By sharing journeys like Chad Dubbeldeโs, CXO Gateway continues to connect global leaders with ideas that inspire change.